Welcome to our dedicated page for Iovance Biotherp SEC filings (Ticker: IOVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on tumor infiltrating lymphocyte (TIL) cell therapies for cancer. These documents offer detailed insight into the company’s financial condition, capital structure, product commercialization, and clinical and regulatory activities.
Iovance’s current reports on Form 8-K, for example, describe quarterly financial results, updates on clinical and commercial progress for Amtagvi and Proleukin, corporate presentations used at healthcare conferences, and material agreements such as an amended and restated open market sale agreement that enables at-the-market offerings of common stock. Other 8-K filings outline executive leadership changes and report press releases related to regulatory milestones, including the approval of Amtagvi in Canada for advanced melanoma after anti-PD-1 and targeted therapy.
On Stock Titan, these SEC filings are paired with AI-powered summaries that highlight key points, helping readers quickly understand the significance of each document without parsing every technical detail. Real-time updates from the EDGAR system ensure that new filings, such as earnings-related 8-Ks, registration statements, or material financing agreements, appear promptly.
Users can also review filings that touch on equity compensation plans and inducement grants made under Nasdaq Listing Rule 5635(c)(4), which shed light on how Iovance uses stock-based incentives. Together, the full-text filings and AI-generated explanations offer a structured view of how Iovance reports its operations, risk factors, and strategic decisions to regulators and investors.
IOVANCE BIOTHERAPEUTICS, INC. Chief Operating Officer Igor Bilinsky reported the vesting of 31,246 restricted stock units on March 5, 2026, which were converted into an equal number of common shares at no exercise price.
To cover mandatory tax withholding on this RSU vesting, 16,628 common shares were withheld by the company at a reference price of $4.58 per share, which the disclosure states is not an open market sale. After these transactions, Bilinsky directly held 125,766 common shares and 62,504 RSUs. The remaining RSUs from this March 5, 2025 grant are scheduled to vest in equal quarterly installments, with each unit representing the right to receive one share of common stock.
IOVANCE Biotherapeutics interim CEO and General Counsel Frederick G. Vogt reported vesting of restricted stock units and related tax withholding. On March 2, 2026, RSUs covering 52,087 shares of common stock vested and were delivered at no cost through derivative exercises.
The company then withheld 22,809 common shares at $3.79 per share to cover mandatory tax obligations, which the filing clarifies was not an open market sale of securities. After these transactions, Vogt directly owned 493,800 shares of common stock, with remaining RSUs scheduled to vest in equal quarterly installments.
IOVANCE BIOTHERAPEUTICS, INC. Chief Operating Officer Igor Bilinsky reported equity award activity tied to restricted stock units. On March 2, 2026, RSUs covering 8,790 and 3,517 shares vested and were converted into common stock at no cash exercise price. This resulted in the issuance of 12,307 shares of common stock. Separately, 6,903 shares of common stock were withheld by the company to cover mandatory tax obligations upon vesting, which the filing notes was not an open market sale. After these transactions, Bilinsky directly owned 111,148 shares of common stock.
IOVANCE BIOTHERAPEUTICS, INC. Chief Regulatory Officer Raj K. Puri reported the vesting of 5,470 restricted stock units (RSUs), which converted into an equal number of common shares on March 2, 2026. Each RSU represents a contingent right to receive one share of common stock.
To cover mandatory taxes on this vesting, the issuer withheld 2,798 common shares at $3.79 per share in a tax-withholding disposition that was not an open market sale. Following these transactions, Puri directly held 218,531 shares of common stock and 21,878 RSUs remaining from a March 1, 2024 grant that will vest in equal quarterly installments.
IOVANCE BIOTHERAPEUTICS, INC. Chief Medical Officer Friedrich Graf Finckenstein reported routine equity compensation activity involving restricted stock units (RSUs) and common stock. On the transaction date, RSUs representing 8,790 shares vested, and additional RSUs representing 3,907 shares were also reported, each RSU corresponding to one share of common stock. These conversions resulted in 12,697 shares of common stock, with 7,122 shares of common stock withheld by the company at $3.79 per share to cover mandatory tax obligations, which the filing specifies is not an open market sale. After these transactions, he directly owned 117,231 shares of common stock, along with remaining RSU holdings noted in the filing that will vest in equal quarterly installments.
IOVANCE BIOTHERAPEUTICS, INC. Chief Commercial Officer Daniel Gordon reported the vesting of performance-based restricted stock units after certain financial milestones were achieved. On February 24, 2026, 120,000 shares of common stock vested from previously granted PSUs, while 30,000 related PSUs were cancelled.
To cover mandatory tax withholding on the vesting, 34,165 shares of common stock were withheld by the company at a price of $3.78 per share, which is described as not being an open market sale. After these transactions, Gordon directly holds 139,381 shares of Iovance common stock.
Iovance Biotherapeutics is a commercial-stage biotech company focused on tumor infiltrating lymphocyte (TIL) cell therapies for solid tumors. Its first commercial product, Amtagvi (lifileucel), is approved in the U.S. and Canada for previously treated advanced melanoma and is given with lymphodepletion and Proleukin.
The company estimates Amtagvi could address over 30,000 advanced melanoma patients annually and is pursuing additional approvals in the UK, Australia, Switzerland and the EU. A Phase 3 trial (TILVANCE-301) is testing lifileucel plus pembrolizumab in frontline melanoma, while the IOV-LUN-202 registrational trial targets previously treated advanced non-squamous NSCLC.
Iovance has centralized manufacturing at its FDA‑approved Iovance Cell Therapy Center in Philadelphia, which has capacity for more than 5,000 patients per year and has produced TIL therapies for over 1,500 patients. As of February 13, 2026, there were 411,961,607 shares of common stock outstanding.
Iovance Biotherapeutics reported strong topline growth for the fourth quarter and full year 2025 while remaining loss-making as it scales commercialization of Amtagvi. Fourth-quarter product revenue reached $86.8M, up from $73.7M a year earlier, contributing to full-year 2025 revenue of $263.5M versus $164.1M in 2024, meeting its $250M–$300M guidance range. Q4 gross margin improved to 50%, but total 2025 costs and expenses of $666.9M led to a net loss of $391.0M, or $(1.09) per share. Cash, cash equivalents and investments were $297.0M as of December 31, 2025, with an investor presentation indicating total cash of about $303M and runway into Q3 2027. Strategically, growth is driven by increasing Amtagvi demand in advanced melanoma, while the pipeline advanced with a U.S. FDA Fast Track designation for lifileucel in second-line advanced non-small cell lung cancer and multiple ongoing registrational and proof-of-concept trials in solid tumors.
IOVANCE BIOTHERAPEUTICS Chief Commercial Officer Daniel Gordon Kirby reported vesting of restricted stock units and related tax withholding. On February 10, 2026, 39,996 RSUs vested and were converted into the same number of common shares at $0 exercise price.
To cover mandatory taxes on this vesting, 16,450 common shares were withheld by the company at $2.60 per share, which the filing specifies is not an open market sale. After these transactions, Kirby directly holds 53,546 common shares and 80,004 RSUs from the February 10, 2025 grant, with remaining RSUs scheduled to vest in equal quarterly installments.
State Street Corporation has filed a Schedule 13G reporting beneficial ownership of common stock of IOVANCE BIOTHERAPEUTICS INC as of 12/31/2025. State Street reports beneficial ownership of 20,161,445 shares, representing 5.1% of the company’s common stock.
State Street reports no sole voting or dispositive power, with 19,204,365 shares subject to shared voting power and 20,161,445 shares subject to shared dispositive power. Subsidiaries involved include SSGA Funds Management and various State Street Global Advisors entities. State Street certifies the holdings are in the ordinary course of business and not for changing or influencing control of Iovance.